BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2053-61. [DOI: 10.1093/ibd/izy102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Luo L, Qing L, Yao C, Liu D, Li Y, Li T, Feng P. Efficacy and safety of hyperbaric oxygen therapy for moderate-to-severe ulcerative colitis: a protocol for a systematic review and meta-analysis. BMJ Open 2021;11:e047543. [PMID: 34183344 DOI: 10.1136/bmjopen-2020-047543] [Reference Citation Analysis]
2 Shah NB, Jolly JA, Horst SN, Peter M, Limper H, Zuckerman AD. Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative. Am J Health Syst Pharm 2019;76:1296-304. [PMID: 31418790 DOI: 10.1093/ajhp/zxz142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Haar GS, Vasudevan A, Curtain CM, van Langenberg DR. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. Res Social Adm Pharm 2021;17:1420-5. [PMID: 33129684 DOI: 10.1016/j.sapharm.2020.10.011] [Reference Citation Analysis]
4 Giese-kim N, Wu M, Dehghan M, Sceats LA, Park K. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Am J Gastroenterol 2020;115:1698-706. [DOI: 10.14309/ajg.0000000000000750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lombardi C, Passalacqua G, Bagnasco D. Severe asthma, biologicals, and auto-injection: Yes, no, may be! Allergy 2020;75:444-5. [PMID: 31318070 DOI: 10.1111/all.13988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Barker DH, Shapiro JM, Lobato D, McQuaid EL, Leleiko NS. Challenges and Approaches to Assessing Medication Adherence in Pediatric Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr 2020;70:759-61. [PMID: 32443027 DOI: 10.1097/MPG.0000000000002727] [Reference Citation Analysis]
7 Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179-91. [PMID: 31118734 DOI: 10.2147/CEG.S150908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Moran K, Null K, Huang Z, Lissoos T, Kane S. Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Adv Ther 2019;36:2260-72. [PMID: 31385283 DOI: 10.1007/s12325-019-01037-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P. Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. Gastroenterol Res Pract 2020;2020:4060648. [PMID: 32411197 DOI: 10.1155/2020/4060648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
11 Ahmed Z, Sarvepalli S, Garber A, Regueiro M, Rizk MK. Value-Based Health Care in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:958-68. [DOI: 10.1093/ibd/izy340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, Lewis JD. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:2082-2092.e10. [DOI: 10.1016/j.cgh.2020.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Schultheiss JPD, Altena S, Clevers MR, Baas D, Jharap B, Fidder HH. Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container. Dig Dis Sci 2021;66:1477-87. [PMID: 32556818 DOI: 10.1007/s10620-020-06395-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ottaviani S, Forien M. [Compliance with biologic agents: Current situation]. Rev Mal Respir 2021;38:698-705. [PMID: 34140211 DOI: 10.1016/j.rmr.2021.06.001] [Reference Citation Analysis]
15 Knowles SR, Alex G. Medication Adherence Across the Life Span in Inflammatory Bowel Disease: Implications and Recommendations for Nurses and Other Health Providers. Gastroenterology Nursing 2020;43:76-88. [DOI: 10.1097/sga.0000000000000467] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:314-20. [PMID: 31671188 DOI: 10.1093/ibd/izz253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
17 Lombardi C, Bagnasco D, Passalacqua G. Biological agents for severe asthma: the evolution of the at-home self-injection approach. Curr Opin Allergy Clin Immunol 2020;20:421-7. [PMID: 32590510 DOI: 10.1097/ACI.0000000000000656] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 2021;13:433-58. [PMID: 33557600 DOI: 10.2217/imt-2021-0011] [Reference Citation Analysis]
19 Moum KM, Moum B, Opheim R. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic. Scand J Gastroenterol 2021;56:545-51. [PMID: 33771086 DOI: 10.1080/00365521.2021.1901308] [Reference Citation Analysis]
20 Brixner D, Mittal M, Rubin DT, Mease P, Liu HH, Davis M, Ganguli A, Fendrick AM. Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. Patient Prefer Adherence 2019;13:1545-56. [PMID: 31571837 DOI: 10.2147/PPA.S215037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study. Gastroenterology 2020;159:1592-1594.e1. [PMID: 32574622 DOI: 10.1053/j.gastro.2020.06.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ramos L, Ramos-Rodríguez J, Barreda R, Gutiérrez-Nicolás F, Carrillo-Palau M, Alonso-Abreu I, Nazco-Casariego J, Quintero E. Adherence to subcutaneous biologic treatment for inflammatory bowel disease. Gastroenterol Hepatol 2021:S0210-5705(21)00169-2. [PMID: 34051312 DOI: 10.1016/j.gastrohep.2021.04.011] [Reference Citation Analysis]
23 Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma 2019;56:872-81. [PMID: 30003833 DOI: 10.1080/02770903.2018.1500584] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]